Selvita receives the Economic Award of the President of Poland

Krakow, 07 May 2015 – Selvita, a global drug discovery company engaged in the development of breakthrough oncology treatments and drug discovery services, was awarded the Economic Award of the President of Poland in the category Innovation.

The award was presented by the President of Poland, Mr. Bronislaw Komorowski during the Final Gala of the 13th Edition of the Economic Award, at the International Fair in Poznan. The Economic Award of the President of Poland is an award granted to the best performing businesses in Poland, which have a significant impact on the Polish economy and help to build country’s positive image both nationally and on the global arena. The Jury nominates the best companies in five categories: Innovation, Global Market Presence, Corporate Governance and CSR, Green Economy and Sustainable Success.

This is the most important award we have ever received – only five companies from Poland can win each year, one in each category. Innovation at Selvita is not only about the technology and equipment we use, or the management techniques we implement. It is mostly about our creative approach to drug discovery” – said Pawel Przewiezlikowski, Selvita’s co-founder and Chief Executive Officer.

06.05.2015 Prezydent Bronislaw Komorowski podczas wizyty w Poznaniu . foto:Wojciech Olkusnik/KPRP UWAGA!!! Zdjęcia pochodzące z oficjalnego serwisu fotograficznego Kancelarii Prezydenta RP mogą być wykorzystywane jedynie w celu ilustrowania materiałów dotyczących działań Prezydenta RP. Jakakolwiek ingerencja w integralność zdjęcia w tym kadrowanie czy obróbka graficzna jest niedozwolona. Wszelkie wykorzystywanie zdjęć pochodzących z oficjalnego serwisu fotograficznego Kancelarii Prezydenta RP w celach komercyjnych lub w materiałach o charakterze politycznym jest zabronione. Publikacja lub kontekst wykorzystania  zdjęcia nie może naruszać dobrego imienia Rzeczpospolitej Polskiej, PrezydentaRP, Jego Rodziny i Kancelarii Prezydenta. Publikujący zdjęcia zobowiązuje się do podpisania ich autora oraz źródła ich pochodzenia.


(photo credits: Wojciech Olkuśnik. Press Office of the President of Poland)

Selvita offers drug discovery services for pharmaceutical and biotechnology companies from the US, Europe, Israel and Brazil and also develops internal early stage oncology programs, which are expected to move to the clinic in 2016. The most advanced programs at Selvita are SEL24, a dual PIM/FLT3 kinase inhibitor for hematopoietic tumors, SEL120 a first-in-class small molecule inhibitor of CDK8, and SEL201 focused on MNK1 / MNK2 kinases in solid tumors.

The company was established in 2007 and currently employs 230 scientists, including 80 PhDs. Its offices are located in Krakow, Poland, Cambridge, UK and Greater Boston Area. Selvita is listed on the Warsaw Stock Exchange (SLV), and has a market cap ~$ 60 MM.